Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors.

Seema Gupta, Abdullah Farooque, J. S. Adhikari, Saurabh Singh, B. S. Dwarakanath

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations


The development of an approach based on the energy-linked modification of DNA repair and cellular recovery processes using 2-deoxy-D-glucose (2-DG; inhibitor of glycolytic ATP production) has shown promising results in a number of model systems of cancer. Following encouraging results on the tolerance and toxicity (acute as well as late effects) of the combination (2-DG and hypofractionated radiotherapy) in Phase I and II clinical trials, its efficacy is currently under evaluation in Phase III clinical trials for glioma patients. Since heterogeneous physiologic and metabolic status in tumors as well as host-tumor interactions influence the local tumor control, which coupled with systemic disturbances could determine the cure (long-term tumor free survival), investigations on the in vivo responses of tumors to the combined treatment have received considerable attention. This communication provides a brief overview on the in vivo studies related to radio- and chemosensitization of tumors by 2-DG, besides the normal tissue toxicity induced by the combined treatment of 2-DG and radiation or chemotherapeutic drugs.

Original languageEnglish (US)
Pages (from-to)S16-20
JournalJournal of cancer research and therapeutics
Volume5 Suppl 1
StatePublished - 2009
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors.'. Together they form a unique fingerprint.

Cite this